Bio-Techne (TECH), a life science company, on Friday announced the launch of a new line of AI-engineered designer proteins aimed at advancing cell therapy and regenerative medicine.
The expanded portfolio, developed under the company's R&D Systems brand, includes advanced proteins like IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable, and Wnt/RSPO agonists.
These proteins are engineered using cutting-edge AI technology and evolutionary protein design to address key needs in cellular therapy, such as improved cell culture performance and optimized cell expansion.
The new products are designed for a variety of applications, including CAR T-cell and tumor-infiltrating lymphocyte (TIL) expansion, stem cell culture, and regenerative medicine.
Will Geist, President of the Protein Sciences Segment at Bio-Techne, stated, "Our growing portfolio combines cutting-edge AI technology and innovative protein engineering, empowering customers with high-performance solutions to enhance cell therapy production and regenerative medicine efforts."
The new products include:
Optimized for cellular therapy applications like CAR T-cell expansion.
Designed for superior regenerative medicine cell differentiation.
A versatile growth factor for stem cell culture, available in both research-use-only (RUO) and GMP formats.
Key reagents for stem cell research and organoid development.
Bio-Techne continues to develop next-generation tools for cell therapy and regenerative medicine research, aiming to provide breakthrough solutions for researchers and clinicians.
Currently TECH is trading at $74.74 down by 0.60%
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.